Gilead Sciences (NASDAQ:GILD) Rating Lowered to “Market Perform” at Leerink Partners

Gilead Sciences (NASDAQ:GILD) was downgraded by research analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a note issued to investors on Tuesday, MarketBeat.com reports. They currently have a $127.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $146.00. Leerink Partners’ price target points to a potential downside of 2.56% from the company’s current price.

Other analysts also recently issued reports about the company. The Goldman Sachs Group increased their price objective on Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research note on Friday, April 17th. Daiwa Securities Group cut their target price on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 19th. Maxim Group upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $165.00 price target for the company in a report on Wednesday, May 20th. Citigroup increased their price target on Gilead Sciences from $156.00 to $165.00 and gave the company a “buy” rating in a research report on Monday, April 13th. Finally, Morgan Stanley dropped their price objective on Gilead Sciences from $168.00 to $166.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 8th. Twenty-five equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $158.33.

Gilead Sciences Stock Up 0.0%

Shares of NASDAQ GILD opened at $130.34 on Tuesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The company has a 50-day moving average price of $129.58 and a 200-day moving average price of $135.47. The stock has a market capitalization of $161.83 billion, a P/E ratio of 17.76 and a beta of 0.32. Gilead Sciences has a 1 year low of $108.46 and a 1 year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The company had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. The firm’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities research analysts forecast that Gilead Sciences will post -0.77 EPS for the current fiscal year.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the completion of the transaction, the chief financial officer owned 171,646 shares in the company, valued at $21,524,408.40. This represents a 1.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O’day sold 15,000 shares of Gilead Sciences stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $126.29, for a total value of $1,894,350.00. Following the sale, the chief executive officer owned 607,133 shares in the company, valued at $76,674,826.57. The trade was a 2.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 77,000 shares of company stock valued at $9,978,740. Insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GILD. Strategic Investment Solutions Inc. IL bought a new stake in shares of Gilead Sciences in the 4th quarter worth approximately $25,000. Vermillion & White Wealth Management Group LLC increased its position in Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 85 shares during the last quarter. Quattro Advisors LLC purchased a new stake in Gilead Sciences in the fourth quarter worth $26,000. Wealth Preservation Advisors LLC raised its stake in shares of Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 81 shares during the period. Finally, Ares Financial Consulting LLC bought a new stake in shares of Gilead Sciences in the fourth quarter valued at $28,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Merck reported that their experimental once-weekly HIV pill kept the virus suppressed in two late-stage trials, a key step that supports upcoming regulatory filings and could position the regimen as a first-of-its-kind treatment. Article Title
• Positive Sentiment: Gilead said it will present new HIV research at AIDS 2026, including long-term efficacy and safety data for lenacapavir and results from its collaboration with Merck, reinforcing investor attention on its HIV franchise. Article Title
• Positive Sentiment: Gilead advanced a long-acting HIV regimen into a new Phase 3 head-to-head trial, signaling continued pipeline progress in one of the company’s most important growth areas. Article Title
• Neutral Sentiment: Gilead announced it will release second-quarter 2026 results on August 4, which keeps the stock in focus but does not provide new financial information yet. Article Title
• Neutral Sentiment: Market coverage noted that Gilead was trending and underperforming some peers intraday, suggesting mixed trading sentiment rather than a clear company-specific shock. Article Title
• Negative Sentiment: Leerink Partners downgraded Gilead to “market perform” from “outperform” and cut its price target to $127 from $146, which may be weighing on the shares. Article Title

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.